| Regeneron Pharmaceuticals, Inc. | (NQ: REGN) |
|
266.97 USD
+2.31 (+0.87%)
|
| View: | Quote | Chart | Options | News | SEC Filings |
from PR Newswire
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
May 15, 2013
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials Read More
from PR Newswire
from PR Newswire
- First quarter EYLEA® (aflibercept) Injection net sales of $314 million in the U.S. and $65 million in rest of world Read More
from PR Newswire
Before the Crowd, How We Found REGN, AMZN and BAC
May 02, 2013
from PR Newswire
from PR Newswire
Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
April 11, 2013
from PR Newswire
from PR Newswire
BioMed Realty To Develop 297,000 Square Feet In New York Fully Leased To Regeneron Pharmaceuticals
April 04, 2013
from PR Newswire
from PR Newswire
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
March 02, 2013
Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology Read More
from PR Newswire
Regeneron Announces Upcoming 2013 Investor Conference Presentations
February 19, 2013
from PR Newswire
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
February 19, 2013
from PR Newswire
Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
February 14, 2013
from PR Newswire
Critical Alerts For JPMorgan Chase, Precision Castparts, Spirit Aerosystems, Regeneron Pharmaceuticals, and Steel Dynamics Released By InvestorsObserver
February 13, 2013
from PR Newswire
Regeneron Announces Receipt of Hart-Scott-Rodino Notice
February 11, 2013
from PR Newswire
ZALTRAP® (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
February 05, 2013
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen Read More
from PR Newswire
Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
January 28, 2013
from PR Newswire
from PR Newswire
Regeneron Announces January 2013 Investor Conference Presentations
December 20, 2012
from PR Newswire
Quarterly Changes to the NASDAQ Q-50 Index
December 17, 2012
Annual Changes to the NASDAQ-100 Index
December 14, 2012
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
